Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Control Release ; 99(2): 301-14, 2004 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-15380639

RESUMEN

N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer carrier containing the anticancer drug doxorubicin bound either by a proteolytically degradable bond (non-targeted PK1 or targeted with alpha-CD71 mAb) or by a hydrolytically degradable bond were synthesised and tested in vivo for various biological properties. Mouse 38C13 B-cell lympoma was used as a well established and defined cell line for this study. 38C13 cells are sensitive to free doxorubicin and IC50 was very low, about 0.014 microM. PK1 showed a strongly decreased cytostatic effect, IC50 being 12.6 microM. alpha-CD71 targeted conjugate, which can be considered as an antibody-targeted form of PK1, had IC50 0.358 microM. HPMA copolymer with doxorubicin bound via a hydrolytically sensitive bond (HYD conjugate) showed a high cytostatic effect with IC50 about 0.052 microM. We demonstrated that HYD conjugate inhibited DNA synthesis and induced p21(Waf1/Cip1) protein expression (p21(Waf1/Cip1) is cyclin-dependent kinase inhibitor which blocks cell cycle progression) as quickly as free doxorubicin, whereas PK1 acted much more slowly. Similarly, apoptosis induction measured by Annexin V binding and Caspase 3 activity was detected later after incubation of cells with PK1 or alpha-CD71 targeted conjugate. Apoptosis was manifested by elevation of bax and bad mRNA levels, which was much more rapid and intense in the case of free doxorubicin and HYD conjugate. Expression of antiapoptotic genes as well as cyclin-dependent kinases was surprisingly not affected.


Asunto(s)
Acrilamidas/síntesis química , Acrilamidas/farmacología , Doxorrubicina/síntesis química , Doxorrubicina/farmacología , Ligandos , Acrilamidas/metabolismo , Animales , Apoptosis/efectos de los fármacos , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Caspasa 3 , Caspasas/efectos adversos , Caspasas/efectos de los fármacos , Caspasas/metabolismo , Ciclo Celular/genética , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/metabolismo , Línea Celular Tumoral , Membrana Celular/efectos de los fármacos , Membrana Celular/patología , Proliferación Celular/efectos de los fármacos , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , ADN/antagonistas & inhibidores , ADN/genética , ADN/metabolismo , Doxorrubicina/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Expresión Génica/efectos de los fármacos , Expresión Génica/genética , Genes myc/efectos de los fármacos , Genes myc/genética , Hidrazonas/síntesis química , Hidrazonas/metabolismo , Hidrazonas/farmacología , Hidrólisis , Concentración 50 Inhibidora , Ratones , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , ARN Mensajero/genética , Receptores de Transferrina/efectos de los fármacos , Receptores de Transferrina/genética , Timidina/metabolismo , Tritio , Proteína X Asociada a bcl-2 , Proteína Letal Asociada a bcl
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA